Chai-2 AI Antibody Design Platform for Drug Discovery

Chai Discovery, founded in 2024, has quickly become one of the most well-funded biotech AI startups. In just over 12 months, the company raised over $225 million and announced a partnership with Eli Lilly to help develop new medicines. The company's algorithm Chai-2 is designed to develop antibodies - the proteins necessary for fighting illnesses. Chai's ambition is to build the 'computer-aided design suite' for molecules. The company says Chai-2 is achieving significant improvements in success rates over other methods for de novo antibody design - building custom antibodies from scratch rather than modifying existing ones. Their latest models can design molecules that have properties suitable for actual drugs, tackling targets that have been out of reach with traditional methods.